| Literature DB >> 34977052 |
Pingting Zhong1,2, Yijun Hu1,3,4, Lei Jiang5, Qingsheng Peng1, Manqing Huang1, Cong Li1,6, Yu Kuang1, Ning Tan7, Honghua Yu1, Xiaohong Yang1.
Abstract
Background: Retinal microvasculature has been associated with coronary artery disease (CAD), but the exact contributory role in coronary total occlusion (CTO) is unclear. We aimed to investigate whether retinal vasculature is associated with CTO and could provide incremental value in the assessment of CTO.Entities:
Keywords: coronary artery disease; coronary total occlusion; optical coherence tomography angiography; prediction; retinal microvasculature
Year: 2021 PMID: 34977052 PMCID: PMC8716542 DOI: 10.3389/fmed.2021.708491
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic and clinical characteristics of included CAD patients (n = 218).
|
|
|
|
| |
|---|---|---|---|---|
|
|
|
| ||
| Age (years), mean ± SD | 58.25 ± 8.6 | 57.74 ± 8.3 | 58.83 ± 8.9 | 0.352 |
| Males, | 191 (87.6) | 94 (81.0) | 97 (95.1) |
|
| Hypertension, | 116 (53.2) | 61 (52.6) | 55 (53.9) | 0.844 |
| BP grade, | 0.793 | |||
| Grade I (reference) | 18 (8.3) | 10 (8.6) | 8 (7.8) | |
| Grade II | 41 (18.8) | 20 (17.2) | 21 (20.6) | |
| Grade III | 56 (25.7) | 31 (26.7) | 25 (24.5) | |
| Diabetic mellitus, | 39 (17.9) | 20 (17.2) | 19 (18.6) | 0.790 |
| Smoker, | 74 (33.9) | 37 (31.9) | 37 (36.3) | 0.496 |
| BMI (kg/m2), mean ± SD | 24.51 ± 3.0 | 24.68 ± 3.1 | 24.31 ± 2.9 | 0.382 |
| LVEF (%), median (IQR) | 64.00 (58.00–68.00) | 66.00 (63.00–69.00) | 60.00 (45.00–65.25) |
|
| Beta- blockers | 53 (24.3) | 26 (22.4) | 27 (26.5) | 0.486 |
| Calcium channel blocker | 42 (19.3) | 19 (16.4) | 23 (22.5) | 0.249 |
| ACEI/ARBs | 70 (32.1) | 38 (32.8) | 32 (31.4) | 0.827 |
| Aspirin | 218 (100) | 116 (100) | 102 (100) | 1.000 |
| Clopidogrel | 219 (100) | 116 (100) | 102 (100) | 1.000 |
| Statin | 220 (100) | 116 (100) | 102 (100) | 1.000 |
| TC (mmol/L), median (IQR) | 4.20 (3.55–5.17) | 4.16 (3.66–5.16) | 4.30 (3.48–5.17) | 0.989 |
| Triglycerides (mmol/L), median (IQR) | 1.56 (1.17–2.14) | 1.56 (1.17–2.16) | 1.57 (1.17–2.14) | 0.765 |
| HDL-C (mmol/L), median (IQR) | 0.95 (0.82–1.10) | 0.93 (0.80–1.13) | 0.95 (0.83–1.06) | 0.732 |
| LDL-C (mmol/L), median (IQR) | 2.81 (2.21–3.55) | 2.79 (2.22–3.51) | 2.86 (2.14–3.56) | 0.879 |
| HbA1C (%), median (IQR) | 5.90 (5.60–6.20) | 5.80 (5.60–6.13) | 5.90 (5.60–6.30) | 0.317 |
| hs-TnT (pg/ml), median (IQR) | 12.45 (9.10–34.33) | 10.25 (7.78–20.03) | 18.15 (11.03–40.90) |
|
| NT-proBNP (pg/mL), median (IQR) | 103.60 (46.15–395.55) | 58.65 (30.88–120.28) | 303.70 (83.30–674.20) |
|
| Gensini score, median (IQR) | 54.00 (28.00–85.00) | 33.50 (22.75–56.00) | 97.00 (67.00–121.50) |
|
CAD, coronary artery disease; CTO, coronary total occlusion; BP, blood pressure; BMI, body mass index; LVEF, left ventricular ejection fraction; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA.
p < 0.05 is considered statistically significant.
The comparisons of retinal vasculature parameters in the study groups (n = 218).
|
|
|
|
|
|
|---|---|---|---|---|
|
|
|
| ||
| Mean | 114.52 ± 13.8 | 114.28 ± 11.5 | 114.79 ± 16.0 | 0.884 |
| Superior | 138.50 ± 23.3 | 137.86 ± 15.9 | 139.23 ± 29.7 | 0.799 |
| Inferior | 146.89 ± 18.7 | 147.05 ± 17.2 | 146.71 ± 20.4 | 0.748 |
| Temporal | 77.16 ± 10.6 | 77.02 ± 9.7 | 77.33 ± 11.6 | 0.881 |
| Nasal | 100.15 ± 17.8 | 99.95 ± 15.1 | 100.38 ± 20.5 | 0.418 |
| Mean | 55.68 ± 3.0 | 56.15 ± 2.6 | 55.14 ± 3.2 | 0.387 |
| Peripapillary | 57.94 ± 3.6 | 58.50 ± 3.0 | 57.31 ± 4.1 | 0.445 |
| Superior-hemi | 58.49 ± 3.8 | 59.11 ± 3.2 | 57.78 ± 4.3 | 0.259 |
| Inferior-hemi | 57.34 ± 3.7 | 57.82 ± 3.1 | 56.80 ± 4.2 | 0.728 |
| Mean | 48.83 ± 2.9 | 49.33 ± 2.5 | 48.26 ± 3.2 | 0.257 |
| Peripapillary | 51.24 ± 3.6 | 51.79 ± 3.2 | 50.62 ± 4.0 | 0.272 |
| Superior-hemi | 51.51 ± 3.9 | 52.11 ± 3.4 | 50.82 ± 4.3 | 0.101 |
| Inferior-hemi | 50.94 ± 3.7 | 51.43 ± 3.2 | 50.38 ± 4.1 | 0.640 |
| Mean SCP | 48.88 ± 3.3 | 49.85 ± 2.4 | 47.77 ± 3.7 |
|
| Parafovea SCP | 51.17 ± 3.8 | 52.56 ± 2.7 | 49.58 ± 4.3 |
|
| Superior hemi in parafovea SCP | 51.37 ± 3.8 | 52.88 ± 2.7 | 49.64 ± 4.2 |
|
| Inferior hemi in parafovea SCP | 50.97 ± 4.1 | 52.25 ± 3.0 | 49.51 ± 4.6 |
|
| Mean DCP | 49.31 ± 5.5 | 50.10 ± 5.2 | 48.41 ± 5.7 | 0.677 |
| Parafovea DCP | 53.77 ± 4.1 | 54.37 ± 4.0 | 53.09 ± 4.2 | 0.467 |
| Superior hemi in parafovea DCP | 54.15 ± 4.2 | 54.79 ± 3.9 | 53.42 ± 4.3 | 0.369 |
| Inferior hemi in parafovea DCP | 53.40 ± 4.3 | 53.95 ± 4.2 | 52.77 ± 4.3 | 0.608 |
| FD300 | 52.96 ± 4.4 | 54.07 ± 3.9 | 51.70 ± 4.6 | 0.283 |
CTO, coronary total occlusion; OR, odd ratio; CI, confidence interval; RNFL, retinal nerve fiber layer; RPC, radial peripapillary capillary; VD, vessel density; FD, foveal density; LVEF, left ventricular ejection fraction; hs-TnT, high-sensitivity troponin T; NT-proBNP, N terminal pro-brain natriuretic peptide.
p < 0.05 is considered statistically significant.
Adjusted for sex, age, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), history of BP grade, history of diabetic mellitus, smoke, LVEF, hs-TnT, NT-proBNP, and Gensini score.
Risk factors for CTO using logistic regression analysis.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
|
| ||||
| Female | Reference | Reference | ||
| Male | 4.540 (1.651–12.486) |
| 5.609 (1.181–26.641) |
|
| LVEF, % | 0.916 (0.883–0.951) |
| 0.916 (0.880–0.954) |
|
| NT-proBNP, pg/mL | 1.001 (1.001–1.002) |
| ||
|
| ||||
| Mean | 1.254 (1.135–1.385) |
| ||
| Parafovea | 1.300 (1.177–1.435) |
| ||
| Superior hemi in parafovea | 1.331 (1.202–1.474) |
| 0.772 (0.685–0.870) |
|
| Inferior hemi in parafovea | 1.209 (1.114–1.311) |
| ||
CTO, coronary total occlusion; OR, odd ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N terminal pro-brain natriuretic peptide; VD, vessel density; SCP, superficial capillary plexus.
p < 0.05 is considered statistically significant.
Figure 1ROC curves of retinal vasculature and clinical variates in differentiating CTO from CAD. ROC, receiver operating characteristic; VD, vessel density; CTO, chronic total occlusion; CAD, coronary artery disease; AUC, area under the curve. Clinical variates refer to sex, left ventricular ejection fraction (LVEF).
Figure 2Example OCT angiograms of DCP in the non-CTO and CTO eyes. Typical 6 × 6 mm high-definition OCT angiograms in the SCP: (A) a non-CTO CAD eye with higher retinal VD (VD of mean, parafovea, superior hemi parafovea and inferior hemi parafovea in the SCP: 55.63, 61.45, 62.13, and 60.77%, respectively). (B) a CTO eye with lower retinal VD (VD of mean, parafovea, superior hemi parafovea and inferior hemi parafovea in the SCP: 36.55, 36.50, 38.37, and 34.62%, respectively). CTO, coronary total occlusion; SCP, superficial capillary plexus; VD, vessel density.